Skip to main content

The news desk

AI news, checked against the source.

What changed in AI, one story at a time. Each one links to its primary source, and facts stay apart from interpretation.

Last updated ·

Friday, October 23UTC

  1. New
    Tempus AIBMS oncology data agreementBusiness & Adoption

    Tempus expands BMS oncology data and AI research agreement

    Tempus says Bristol Myers Squibb signed a multi-year agreement to license de-identified oncology data through 2031 and use its Lens AI research platform. The announcement describes research access and hoped-for drug-discovery benefits; it does not report a new approved therapy or measured clinical improvement.

    Tempus AI1 source

Free, email only

Unlock the full brief free.

  • Thirty days of stories to browse, not seven
  • On every story: what to check, each source and why it matters
  • The same signup unlocks every free tool
Continue with Google and subscribeContinue with Apple and subscribe

Continuing subscribes the email on that account to Work Worth Doing, my newsletter, the same as the form below, and unlocks every free tool in this browser. We only receive your email address. Unsubscribe in one click.

This is not an account: there is no password, and the unlock is a cookie in this browser. You also join Work Worth Doing, Demetri Panici's newsletter, every week: what I built and what changed in AI. We'll email you a link to confirm, and you can unsubscribe in one click. The same signup unlocks every free tool on the site. How your email is handled.

Already subscribed? Enter the same email to unlock this browser. You won't be signed up twice.

Days are UTC. Some sources report an exact time and others only a date; both are placed on their UTC day.